Eloralintide

Oct 13, 2026 View: 106 Leave a message Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) compared to 34.4 lbs (14.8%) with tirzepatide 15 mg Participants taking EloraTZP lowered their A1C by up to an average of 2.9% compared to 2.4% with tirzepatide 15 mg Based on results of this 48-week Phase 2b study, Lilly will initiate Phase 3 trials of EloraTZP in Q4 2026 INDIANAPOLIS, Sept. 30, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP, an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist, in 367 adults with obesity or overweight and type 2 diabetes. At 48 weeks, all combinations of EloraTZP met the primary and secondary endpoints, delivering substantial weight loss and A1C reduction. Results from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. EloraTZP was developed to simultaneously activate three complementary nutrient-stimulated hormones: GIP, GLP-1, and amylin, with minimal activity at the calcitonin receptor. These substances are released naturally by the body after eating, with each acting through its own distinct receptor to help regulate hunger and blood sugar.1 "Obesity and type 2 diabetes are interconnected, and we are seeing the potential benefit of targeting multiple hormonal pathways to address both," said Liana K. Billings, M.D., Director of Clinical and Genetics Research in Diabetes and Cardiometabolic Disease at Endeavor Health, Evanston, Illinois, and lead author. "Across the dose combinations studied with eloralintide and tirzepatide, participants had substantial weight loss alongside meaningful reductions in A1C. These are outcomes that matter to patients. We need to continue building on these findings so that, in the future, we can offer patients more treatment options that address both weight and glucose and better reflect the complexity of living with type 2 diabetes and obesity." Eloralintide alone reduced body weight by up to an average of 28.6 lbs (12.3%) and A1C by up to an average of 1.4%, while tirzepatide 15 mg reduced body weight by an average of 34.4 lbs (14.8%) and A1C by 2.4%. Participants taking EloraTZP lost up to an average of 54.1 lbs (23.3%) and lowered their A1C by up to an average of 2.9% at 48 weeks, beyond what either medicine achieved alone. Phase 2 Efficacy Estimand Results2 Primary Endpoint: Change in body weight from an avg. baseline of 232.4 lbs (105.4 kg)i Secondary endpoint: Change in A1C from an avg. baseline of 8.1% Elora 3 mg + TZP 5 mg -13.2 % -30.7 lbs -2.2 % Elora 6 mg + TZP 5 mg -19.4 % -45.1 lbs -2.7 % Elora 6 mg + TZP 10 mg -19.9 % -46.2 lbs -2.6 % Elora 9 mg + TZP 15 mg -23.3 % -54.1 lbs -2.9 % TZP 15 mg -14.8 % -34.4 lbs -2.4 % Elora 3 mg -8.2 % -19.1 lbs -1.1 % Elora 6 mg -12.3 % -28.6 lbs -1.4 % Elora 9 mg -11.1 % -25.8 lbs -1.3 % Placebo -3.0 % -7.0 lbs -0.3 % iPrimary endpoint was percent change in body weight for EloraTZP vs. placebo. All other comparisons were secondary endpoints. The most common adverse events were gastrointestinal-related and generally mild or moderate, occurring primarily during dose escalation. These events were seen more frequently in the combination arms than with eloralintide or tirzepatide alone. Treatment discontinuation rates due to adverse events were 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide, 2.9% with tirzepatide and 16.7% with placebo. "Lilly continues to pioneer new medicines for people living with obesity and diabetes, building on our scientific track record with tirzepatide, the first approved GIP and GLP-1 dual agonist, and retatrutide, our investigational triple agonist," said Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health. "EloraTZP represents our next frontier, pairing a selective amylin receptor agonist with tirzepatide, which could be an additive and more physiological approach to managing metabolic health. We are highly encouraged by our Phase 2 results with EloraTZP and look forward to quickly initiating Phase 3 studies." Eloralintide is already being evaluated as a single agent in Phase 3 trials for the treatment of obesity. Lilly plans to initiate Phase 3 studies of an EloraTZP co-formulation product by the end of 2026 using an optimized escalation schedule. About EloraTZP EloraTZP is an investigational combination of eloralintide, a selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist and the active ingredient in Zepbound and Mounjaro. By engaging both amylin and incretin pathways concurrently, EloraTZP has the potential to improve weight and blood sugar through the body's naturally occurring metabolic signals. In the Phase 2b study (NCT06603571), eloralintide and tirzepatide were administered as separate injections in adults with obesity or overweight and type 2 diabetes. Lilly plans to advance an EloraTZP co-formulation product into Phase 3 by the end of 2026. About eloralintide Eloralintide is an investigational once-weekly, selective amylin receptor agonist previously known as LY3841136.3,4 Eloralintide has the potential to decrease calorie intake, and the effects are likely mediated by affecting satiety, or the feeling of fullness. Phase 3 trials of eloralintide for the treatment of obesity and in adults with obesity or overweight with or without type 2 diabetes are currently ongoing. Lilly has also conducted a Phase 2b study (NCT06230523) comparing the efficacy and safety of once-weekly eloralintide with placebo in adults with obesity or overweight and at least one weight-related comorbidity without type 2 diabetes.5 About Zepbound (tirzepatide) injection Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity. About the study The Phase 2b study (NCT06603571) was a 48-week, parallel-group, double-blind, placebo-controlled study to investigate weight management with eloralintide and Zepbound, alone or in combination, in adult participants with obesity or overweight with type 2 diabetes. The trial randomized 367 participants in the U.S. and Argentina in a 1:1:1:1:1:1:1:1:1:1 ratio to placebo, eloralintide, tirzepatide or EloraTZP. The primary objective of the study was to demonstrate that eloralintide in combination with Zepbound is superior to placebo in percent change in body weight from baseline at 48 weeks. All participants taking eloralintide started the study at 1 mg or 3 mg and escalated to their final target dose of 6 mg or 9 mg. All participants taking a combination of eloralintide and tirzepatide started the study at eloralintide 1 mg or 3 mg and tirzepatide 2.5 mg and escalated every four weeks until reaching their target dose. All participants taking tirzepatide started the study at 2.5 mg and escalated every four weeks until reaching their target dose of 15 mg. For some participants taking eloralintide as an add-on to tirzepatide, eloralintide was administered at week 24 starting with 3 mg and escalated to 6 mg after four weeks. Endnotes and References 1,Hayes MR, Mietlicki-Baase EG, Kanoski SE, De Jonghe BC. Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu Rev Nutr. 2014;34:237-260. 2,The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) for 48 weeks. 3,Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74 (Supplement_1):849-P. https://doi.org/10.2337/db25-849-P 4,Bhattachar SN, Tham L-S, Tidemann-Miller B, et al. 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity-Phase 1 Proof of Concept. Diabetes 2025;74 (Supplement_1):882-P. https://doi.org/10.2337/db25-882-P 5,Eli Lilly & Company. (November 6, 2025). Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Eli Lilly and Company News Release. https://lilly.gcs-web.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated GenoHope Biotech Ltd. A leading manufacturer of GLP-1 API Approal by FDA Welcome any Inquiry WhatsApp/Tel:+8613833133635 Email:info@genohopebio.com Send Inquiry